Lista de obras - Massimo Offidani - Dominio Público Uruguay

18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease

artículo científico publicado en 2015

A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patients

artículo científico publicado en 2007

A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma.

artículo científico publicado en 2016

A predictive model of varicella-zoster virus infection after autologous peripheral blood progenitor cell transplantation.

artículo científico publicado en 2001

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).

artículo científico publicado en 2016

Acycloguanosine for the treatment of aplastic anaemia ⬇️

artículo científico publicado el 1 de febrero de 1991

Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma ⬇️

artículo científico publicado el 4 de abril de 2013

Adherence to international guidelines for the treatment of invasive aspergillosis in acute myeloid leukaemia: feasibility and utility (SEIFEM-2008B study).

artículo científico publicado en 2010

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials

artículo científico publicado en 2013

An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma

artículo científico publicado en 2014

Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial

scientific article published on 31 January 2011

Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma Registry

artículo científico publicado en 2012

Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis.

artículo científico publicado en 2016

Autologous transplantation and maintenance therapy in multiple myeloma

artículo científico publicado en 2014

Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial data.

artículo científico publicado en 2014

Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia.

artículo científico publicado en 2013

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients

artículo científico publicado en 2010

Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.

artículo científico publicado en 2013

Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation

artículo científico publicado en 2012

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

artículo científico publicado en 2010

Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study

scientific article published on 05 February 2014

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial

artículo científico publicado en 2010

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival

artículo científico publicado en 2014

Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration.

artículo científico publicado en 2016

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

artículo científico publicado en 2015

Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study

Caspofungin for the treatment of candidaemia in patients with haematological malignancies.

artículo científico publicado en 2009

Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial

artículo científico publicado en 2015

Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders.

artículo científico publicado en 2004

Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy.

artículo científico publicado en 2004

Comparison of two regimens for the treatment of elderly patients with acute lymphoblastic leukaemia (ALL).

artículo científico publicado en 2005

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

artículo científico publicado en 2011

Conditioning regimen with BCNU, etoposide, cytarabine and melphalan plus amifostine for outpatient autologous stem cell transplant: feasibility and outcome in 97 patients with lymphoma

artículo científico publicado en 2013

Diagnostic value of C-reactive protein in discriminating fungal from nonfungal pulmonary infiltrates in patients with hematologic malignancies

scientific article published on 15 February 2006

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study.

artículo científico publicado en 2013

Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients.

artículo científico publicado en 2011

Gemcitabine alone or combined with cisplatin in relapsed or refractory multiple myeloma

artículo científico publicado en 2002

Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles

article

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

artículo científico publicado en 2015

How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions.

artículo científico publicado en 2011

Infection complications in an unselected cohort of patients with multiple myeloma treated with lenalidomide combinations.

artículo científico publicado en 2012

Infectious complications in adult acute lymphoblastic leukemia (ALL): experience at one single center.

artículo científico publicado en 2004

Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide ⬇️

artículo científico publicado el 21 de febrero de 2011

Introduction to "Immunotherapies for Multiple Myeloma"

artículo científico publicado en 2020

Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma.

artículo científico publicado en 2016

Ixazomib for the treatment of multiple myeloma.

artículo científico

Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.

artículo científico publicado en 2016

Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia

artículo científico publicado en 2013

Long-term hematologic reconstitution after autologous peripheral blood progenitor cell transplantation: a comparison between controlled-rate freezing and uncontrolled-rate freezing at 80 degrees C

artículo científico publicado en 2003

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis

artículo científico publicado en 2018

Mobilization-driven postconsolidation therapy in elderly patients with acute myeloid leukemia: feasibility and efficacy of autologous stem cell transplantation versus low-dose gemtuzumab ozogamicin

scientific article published on 28 May 2014

Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment

artículo científico publicado en 2020

Oral ixazomib maintenance therapy in multiple myeloma.

artículo científico publicado en 2015

Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone

artículo científico publicado en 2006

Outcome and toxicity in the modern era of new drugs for multiple myeloma: a reappraisal for comparison with future investigational trials.

artículo científico publicado en 2010

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)

Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas

scientific article published on 01 May 2007

Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma

artículo científico publicado en 2012

Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres.

artículo científico publicado en 2002

Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial

artículo científico publicado en 2018

Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data

artículo científico publicado en 2014

Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study).

artículo científico publicado en 2015

Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Grupp

artículo científico publicado en 2015

Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients

artículo científico publicado en 2011

Primary plasma cell leukemia in the era of new drugs: has something changed?

artículo científico publicado en 2011

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.

artículo científico publicado en 2016

Renal failure in multiple myeloma: something new on the horizon.

artículo científico publicado en 2017

Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia

artículo científico publicado en 2014

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

artículo científico publicado en 2015

Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the SEIFEM-D registry

artículo científico publicado en 2015

Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment

scientific article published on 27 September 2011

Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma.

artículo científico publicado en 2016

Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis.

artículo científico publicado en 2004

Second malignancy after treatment of adult acute myeloid leukemia: cohort study on adult patients enrolled in the GIMEMA trials

artículo científico publicado en 2004

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

artículo científico publicado en 2014

Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide/ anthracycline-based therapy.

artículo científico publicado en 2008

Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma

artículo científico publicado en 2009

Smoldering multiple myeloma: to treat or not to treat.

artículo científico publicado en 2015

Stem Cell Transplantation in Multiple Myeloma.

artículo científico publicado en 2016

Technetium-99m sestamibi scintigraphy is sensitive and specific for the staging and the follow-up of patients with multiple myeloma: a multicentre study on 397 scans

artículo científico publicado en 2007

ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myeloma

artículo científico publicado en 2010

Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma

scientific article published on 25 March 2011

Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma

artículo científico publicado en 2006

Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma

artículo científico publicado en 2007

Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study

artículo científico publicado en 2008

The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2.

artículo científico publicado en 2013

The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)

artículo científico publicado en 2015

Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome.

artículo científico publicado en 2013

Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma.

artículo científico publicado en 2016

Triplet vs. doublet drug regimens for managing multiple myeloma.

artículo científico publicado en 2017

Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma.

artículo científico publicado en 2017

Very low rate of readmission after an early discharge outpatient model for autografting in multiple myeloma patients: an Italian multicenter retrospective study.

artículo científico publicado en 2014

Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns.

artículo científico publicado en 2015

Lista de obras de Massimo Offidani

18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease

A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patients

A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma.

A predictive model of varicella-zoster virus infection after autologous peripheral blood progenitor cell transplantation.

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).

Acycloguanosine for the treatment of aplastic anaemia ⬇️

Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma ⬇️

Adherence to international guidelines for the treatment of invasive aspergillosis in acute myeloid leukaemia: feasibility and utility (SEIFEM-2008B study).

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials

An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma

Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial

Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma Registry

Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis.

Autologous transplantation and maintenance therapy in multiple myeloma

Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial data.

Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia.

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients

Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.

Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival

Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration.

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study

Caspofungin for the treatment of candidaemia in patients with haematological malignancies.

Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial

Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders.

Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy.

Comparison of two regimens for the treatment of elderly patients with acute lymphoblastic leukaemia (ALL).

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

Conditioning regimen with BCNU, etoposide, cytarabine and melphalan plus amifostine for outpatient autologous stem cell transplant: feasibility and outcome in 97 patients with lymphoma

Diagnostic value of C-reactive protein in discriminating fungal from nonfungal pulmonary infiltrates in patients with hematologic malignancies

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study.

Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients.

Gemcitabine alone or combined with cisplatin in relapsed or refractory multiple myeloma

Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions.

Infection complications in an unselected cohort of patients with multiple myeloma treated with lenalidomide combinations.

Infectious complications in adult acute lymphoblastic leukemia (ALL): experience at one single center.

Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide ⬇️

Introduction to "Immunotherapies for Multiple Myeloma"

Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma.

Ixazomib for the treatment of multiple myeloma.

Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.

Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia

Long-term hematologic reconstitution after autologous peripheral blood progenitor cell transplantation: a comparison between controlled-rate freezing and uncontrolled-rate freezing at 80 degrees C

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis

Mobilization-driven postconsolidation therapy in elderly patients with acute myeloid leukemia: feasibility and efficacy of autologous stem cell transplantation versus low-dose gemtuzumab ozogamicin

Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment

Oral ixazomib maintenance therapy in multiple myeloma.

Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone

Outcome and toxicity in the modern era of new drugs for multiple myeloma: a reappraisal for comparison with future investigational trials.

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)

Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas

Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma

Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres.

Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial

Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data

Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study).

Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Grupp

Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients

Primary plasma cell leukemia in the era of new drugs: has something changed?

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.

Renal failure in multiple myeloma: something new on the horizon.

Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the SEIFEM-D registry

Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment

Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma.

Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis.

Second malignancy after treatment of adult acute myeloid leukemia: cohort study on adult patients enrolled in the GIMEMA trials

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide/ anthracycline-based therapy.

Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma

Smoldering multiple myeloma: to treat or not to treat.

Stem Cell Transplantation in Multiple Myeloma.